Top Markets
Coin of the day
Evogene Ltd. Evogene Ltd.

Evogene Ltd.

EVGN
Rangering i aksjer #40996
Evogene Ltd. is a computational biology firm specializing in the identification... Evogene Ltd. is a computational biology firm specializing in the identification and advancement of products across human health and agricultural sectors. Its proprietary Computational Predictive Biology (CPB) platform leverages deep biological insights, big data, and artificial intelligence to precisely uncover and guide the creation of life science solutions, including novel microbes, small molecules, and genetic components. The company operates through distinct divisions: Agriculture, Human Health, and Industrial Applications. The Agriculture division concentrates on improving crop performance through the development of advanced seed traits, agricultural chemicals, and biological products for crops like corn, soybean, wheat, rice, and cotton. The Human Health division focuses on pioneering microbiome-based treatments for conditions such as immuno-oncology, gastrointestinal ailments, and antibiotic-resistant infections, and also offers medical cannabis products. The Industrial Applications segment is dedicated to developing improved castor bean varieties for various industrial feedstock requirements. Evogene has a global footprint, conducting business in the United States, Israel, Brazil, and other international markets. It maintains significant partnerships, including agricultural collaborations with BASF SE, Corteva, and Bayer, and a medical cannabis development agreement with Cannbit Ltd. through its subsidiary, Canonic Ltd. Established in 1999, Evogene Ltd. is headquartered in Rehovot, Israel.
Aksjekurs
$0.61559387
Markedsverdi
$53.04K
Endring (1 dag)
2.37%
Endring (1 år)
-51.33%
Land
IL
Handel Evogene Ltd. (EVGN)

Kategori

P/E-forhold for Evogene Ltd. (EVGN)
P/E-forhold per 2026 TTM: 0
Ifølge Evogene Ltd. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Evogene Ltd. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
28.05 -
US
31.14 -
NL
- -
CH
- -
KR
19.30 -
BE
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.